TaiwanJ Pharmaceuticals Co., Ltd.
6549
Rank in Stocks
#27393
TaiwanJ Pharmaceuticals Co., Ltd. operates as a specialized biotech firm... TaiwanJ Pharmaceuticals Co., Ltd. operates as a specialized biotech firm dedicated to the research, development, and commercialization of small molecule therapeutics. Initially, its focus within Taiwan has been on tackling chronic organ inflammation stemming from metabolic, autoimmune, or infectious causes. The company's growing pipeline also features specific compounds like JKB-122 and JKB-121, alongside a collection of innovative chemical entities. These new drugs are being developed to address persistent liver conditions and allergic respiratory ailments, such as asthma. TaiwanJ's comprehensive product portfolio is engineered to combat a wide array of diseases, encompassing hepatic inflammation and fibrosis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), various autoimmune disorders, asthma, and atopic dermatitis (eczema). Established in 2011, the company's operations are headquartered in Zhubei, Taiwan.
Share Price
$0.19052787
Last synced: 2026-11-10
Market Cap
$15.27M
Change (1 day)
0.00%
Change (1 year)
-26.09%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade TaiwanJ Pharmaceuticals Co., Ltd. (6549)
Category
Healthcare
EPS for TaiwanJ Pharmaceuticals Co., Ltd. (6549)
EPS as of June 2026 TTM: $-0.01
According to TaiwanJ Pharmaceuticals Co., Ltd.'s latest financial reports, its current EPS (TTM) is $-0.01. At the end of 2025 the company had an EPS of $-0.01, equal to its 2024 EPS of $-0.01.
EPS history for TaiwanJ Pharmaceuticals Co., Ltd. from 2013 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.01 | -29.00% |
| 2025 | $-0.01 | 9.09% |
| 2024 | $-0.01 | 238.46% |
| 2023 | 0.00 | -93.52% |
| 2022 | $-0.04 | 591.38% |
| 2021 | $-0.01 | -72.90% |
| 2020 | $-0.02 | 756.00% |
| 2019 | 0.00 | -97.82% |
| 2018 | $-0.11 | -1.29% |
| 2017 | $-0.12 | -23.64% |
| 2016 | $-0.15 | 58.65% |
| 2015 | $-0.10 | -20.07% |
| 2014 | $-0.12 | -16.60% |
| 2013 | $-0.14 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -220,663.38% |
US
|
|
| $-7.07 | 99,477.46% |
US
|
|
| $-5.29 | 74,407.04% |
AU
|
|
| $12.88 | -181,509.86% |
BE
|
|
| $21.56 | -303,761.97% |
NL
|
Questions about TaiwanJ Pharmaceuticals Co., Ltd.'s earnings per share (EPS)
What is TaiwanJ Pharmaceuticals Co., Ltd.'s earnings per share (EPS)?
TaiwanJ Pharmaceuticals Co., Ltd.'s earnings per share (EPS) over the last twelve months is $-0.01, as of Jun 2026.
What was TaiwanJ Pharmaceuticals Co., Ltd.'s earnings per share (EPS) in 2025?
In 2025, TaiwanJ Pharmaceuticals Co., Ltd.'s earnings per share (EPS) was $-0.01, compared with $-0.01 in 2024.
How has TaiwanJ Pharmaceuticals Co., Ltd.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, TaiwanJ Pharmaceuticals Co., Ltd.'s earnings per share (EPS) was highest in 2023 (0.00) and lowest in 2022 ($-0.04).
How does TaiwanJ Pharmaceuticals Co., Ltd.'s earnings per share (EPS) compare with similar companies?
TaiwanJ Pharmaceuticals Co., Ltd.'s earnings per share (EPS) ($-0.01) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.